BR112021020402A2 - Moduladores da via de resposta ao estresse integrada - Google Patents

Moduladores da via de resposta ao estresse integrada

Info

Publication number
BR112021020402A2
BR112021020402A2 BR112021020402A BR112021020402A BR112021020402A2 BR 112021020402 A2 BR112021020402 A2 BR 112021020402A2 BR 112021020402 A BR112021020402 A BR 112021020402A BR 112021020402 A BR112021020402 A BR 112021020402A BR 112021020402 A2 BR112021020402 A2 BR 112021020402A2
Authority
BR
Brazil
Prior art keywords
stress response
modulators
integrated stress
response pathway
compounds
Prior art date
Application number
BR112021020402A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis Palmer Christopher
John Brown Christopher
Simon Walter Daryl
Holly Atton
Irena Reboule
Lindsay Carr James
Jonathan Shine
Marissa Flower
Michael Corr
Mohamad Sabbah
Scott Sadler
Serge Convers-Reignier
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of BR112021020402A2 publication Critical patent/BR112021020402A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Semiconductor Integrated Circuits (AREA)
BR112021020402A 2019-04-23 2020-04-22 Moduladores da via de resposta ao estresse integrada BR112021020402A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19170504 2019-04-23
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
BR112021020402A2 true BR112021020402A2 (pt) 2021-12-07

Family

ID=70289816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020402A BR112021020402A2 (pt) 2019-04-23 2020-04-22 Moduladores da via de resposta ao estresse integrada

Country Status (15)

Country Link
US (2) US12258338B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959198A1 (cg-RX-API-DMAC7.html)
JP (2) JP7590343B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004105A (cg-RX-API-DMAC7.html)
CN (1) CN113993850B (cg-RX-API-DMAC7.html)
AU (2) AU2020261234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020402A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002772A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014292A2 (cg-RX-API-DMAC7.html)
IL (1) IL287379B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021012903A (cg-RX-API-DMAC7.html)
PE (1) PE20220961A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111119PA (cg-RX-API-DMAC7.html)
WO (1) WO2020216766A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108151B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) * 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004677A (es) * 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
WO2022212902A1 (en) * 2021-04-02 2022-10-06 Altos Labs, Inc. Modulators of integrated stress response pathway
AU2023384649A1 (en) 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
CN121986087A (zh) 2023-10-13 2026-05-05 国立研究开发法人国立精神·神经医疗研究中心 神经保护剂
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639761B1 (en) 1999-12-02 2003-10-28 Seagate Technology Llc Micro-actuator damping and humidity protection
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
US7915433B2 (en) 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
WO2017046739A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
DE102017213834A1 (de) * 2017-08-08 2019-02-14 Robert Bosch Gmbh Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
JP2022530049A (ja) 2022-06-27
PE20220961A1 (es) 2022-06-10
AU2026203062A1 (en) 2026-05-07
WO2020216766A1 (en) 2020-10-29
SG11202111119PA (en) 2021-11-29
JP2025024086A (ja) 2025-02-19
IL287379B1 (en) 2025-07-01
US20220227747A1 (en) 2022-07-21
IL287379B2 (en) 2025-11-01
US12258338B2 (en) 2025-03-25
JP7878648B2 (ja) 2026-06-23
CA3137213A1 (en) 2020-10-29
US20250188071A1 (en) 2025-06-12
CO2021014292A2 (es) 2022-04-29
CN113993850A (zh) 2022-01-28
IL287379A (en) 2021-12-01
AU2020261234A1 (en) 2021-11-11
MX2024015479A (es) 2025-02-10
ZA202108151B (en) 2026-04-29
EP3959198A1 (en) 2022-03-02
MX2021012903A (es) 2022-01-18
AU2020261234B2 (en) 2026-02-05
KR20220004105A (ko) 2022-01-11
CL2021002772A1 (es) 2022-07-29
JP7590343B2 (ja) 2024-11-26
CN113993850B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
CO2021014292A2 (es) Moduladores de la vía de respuesta integrada al estrés
BR112022012643A2 (pt) Moduladores da via de resposta ao estresse integrada
BR112022014706A2 (pt) Moduladores da via de resposta integrada ao estresse
BR112021020106A2 (pt) Moduladores da via de resposta ao estresse inte-grado
Vucicevic et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112022021735A2 (pt) Compostos úteis para inibir cinase ret
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
MX2020012041A (es) Formulacion farmaceutica.
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112016016844A2 (pt) Compostos heterocíclicos
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
BR112013023984A2 (pt) derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
BR112014016157A2 (pt) derivados heterobicíclicos como inibidores de vhc
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
UY38488A (es) Derivados de pirazol y su uso en medicina
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
BR112014016007A8 (pt) derivados de quinazolinona como inibidores de vhc
BR112018073743A2 (pt) composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]